Why is Coloplast stock sliding today?

Coloplast shares dropped 3.3% to DKK 431.9 in Copenhagen trading after JPMorgan delivered a sharp analyst downgrade, moving its rating to Underweight from Neutral and cutting its December 2027 price target to DKK 377 from DKK 484 — a reduction of roughly 22%. Analyst Anchal Verma contended that the risk/reward balance is clearly tilted to the downside, noting that shares trade at a price-to-earnings ratio of 35.35, representing about a 20% premium to the broader medtech sector even as earnings growth runs below sector peers.

A central pillar of JPMorgan's bearish case is leadership uncertainty. The bank expects the company's incoming CEO to revisit and likely lower medium-term financial targets when full-year results are released on November 3, a conclusion informed by management commentary during the fiscal third-quarter update. Analysts also flagged soft margins in that same Q3 period as a further near-term sentiment drag, while short interest was already elevated heading into today's session.

The broader market backdrop offered little relief. The OMX Copenhagen 20 was already lower in the previous session, and global equities came under renewed pressure, with major U.S. indexes trading in negative territory today. The stock's 52-week range of DKK 369.7 to DKK 637.8 highlights how far shares have retreated from their highs, and today's decline adds to an extended period of underperformance for the Danish medtech company.

Taken together, the JPMorgan downgrade acted as the decisive trigger, crystallizing existing concerns around valuation, margin pressure and strategic uncertainty ahead of the pivotal November guidance update, and pushing Coloplast to an intraday low of DKK 427.8 during today's session.

This article was generated with the support of AI and reviewed by an editor. For more information, see our Terms & Conditions.